Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial (PreNATUS)

This study is ongoing, but not recruiting participants.
Columbia University
George Washington University
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Natera, Inc. Identifier:
First received: March 1, 2012
Last updated: October 28, 2014
Last verified: October 2014
This prospective blinded study will assess the diagnostic capability of an informatics enhanced SNP based technology (Parental Support) to identify pregnant women who are carrying a fetus with an aneuploidy from fee floating DNA in the maternal blood.

Condition Intervention
Trisomy 13
Trisomy 18
Trisomy 21
Procedure: Blood Draw

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial (PreNATUS)

Resource links provided by NLM:

Further study details as provided by Natera, Inc.:

Primary Outcome Measures:
  • Sensitivity and Specificity of the test to diagnose aneuploidy in a fetus at chromosomes 13, 18, 21, X and Y. [ Time Frame: Between first trimester screening (10-14 weeks GA) and invasive testing (amniocentesis or CVS). ] [ Designated as safety issue: No ]
    The primary objective is to determine the diagnostic capability of the test to detect autosomal aneuploidy (chromosomes 13, 18, 21) and sex aneuploidy (X and Y).

Biospecimen Retention:   Samples With DNA
Plasma Sample Prepared DNA

Estimated Enrollment: 1000
Study Start Date: January 2012
Estimated Study Completion Date: December 2015
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Pregnant Women
Pregnant Women with elevated risk of trisomic pregnancy
Procedure: Blood Draw
Blood will be drawn from the mother and father


Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Pregnant Women

Inclusion Criteria:

  1. Singleton pregnancy
  2. Gestational age between 8 weeks 0 days and 23 weeks, 6 days by best obstetrical estimate
  3. Mother has a high or moderate risk for trisomy
  4. Mother is planning to have or has had an amniocentesis or chorionic villus sampling (CVS) procedure

Exclusion Criteria:

  1. Unavailability of the father to provide a genetic sample (e.g. sperm donor, non-paternity)
  2. Egg donor used
  3. Mother or father have known chromosomal abnormalities (including known balanced translocations)
  4. Participation in the study in a previous pregnancy
  5. Pregnancy is a result of IVF with pre-implantation genetic diagnosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01545674

  Show 29 Study Locations
Sponsors and Collaborators
Natera, Inc.
Columbia University
George Washington University
National Institutes of Health (NIH)
Principal Investigator: Ronald Wapner, MD Columbia University
  More Information

Additional Information:
Responsible Party: Natera, Inc. Identifier: NCT01545674     History of Changes
Other Study ID Numbers: GSN012B 
Study First Received: March 1, 2012
Last Updated: October 28, 2014
Health Authority: United States: Institutional Review Board
United States: Federal Government

Keywords provided by Natera, Inc.:
Trisomy 18
Edwards Syndrome
Non-invasive Prenatal Diagnosis
Prenatal Blood Test
Prenatal Aneuploidy Screening
Trisomy 13
Trisomy 21
Down Syndrome
Turner Syndrome

Additional relevant MeSH terms:
Down Syndrome
Abnormalities, Multiple
Chromosome Aberrations
Chromosome Disorders
Chromosome Duplication
Congenital Abnormalities
Genetic Diseases, Inborn
Intellectual Disability
Nervous System Diseases
Neurobehavioral Manifestations
Neurologic Manifestations
Pathologic Processes processed this record on May 25, 2016